

Table SI. Patient characteristics.

Characteristic	N-1	N-2	N-3	T-1	T-2	T-3
Age, years	66	77	76	70	74	70
Sex	M	M	F	M	F	M
Stage	IV	IV	IV	IV	IV	IV
<i>EGFR</i> mutation status	Exon 19 deletion	Exon 19 deletion	Exon 19 deletion	Exon 21 L858R	Exon 21 L858R	Exon 21 L858R
Duration of gefitinib dosing, days	741	936	326	42	81	119
Days since first onset	40	683	172	81	41	70
Hepatic injury ^a	Gr 1 ^c	Gr 1 ^c	Gr 1 ^c	Gr 3	Gr 3	Gr 3
AST/ALT ^b	61/45	45/32	26/30	150/239	215/296	232/376

^aCommon Terminology Criteria for Adverse Events (CTCAE) v5.0; ^bthis row indicates maximum values of AST and ALT; ^cthese were transient elevations and improved without discontinuation of gefitinib. EGFR, epidermal growth factor receptor; ND, not detected; D, detected; NA, not applicable; AST, aspartate transaminase; ALT, alanine transaminase; T, toxicity; N, no toxicity.